Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relacorilant and Enzalutamide in High-Risk Localized Prostate Cancer
NCT05726292Phase 2Recruiting
- Sponsor
- University of Chicago
- Start
- Jan 2025
- Primary completion
- Oct 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in prostate cancer (PCa) comparing Relacorilant + Enzalutamide + ADT with Placebo + Enzalutamide + ADT (2 arms). Primary endpoint: Response Rate at 24 weeks. Started Jan 2025; status: recruiting.
02
Drugs
relacorilant
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05726292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05726292.